DK1146872T3 - Anvendelse af angiotensin II-receptorantagonister til behandling af akut myokardieinfarkt - Google Patents

Anvendelse af angiotensin II-receptorantagonister til behandling af akut myokardieinfarkt

Info

Publication number
DK1146872T3
DK1146872T3 DK00902628T DK00902628T DK1146872T3 DK 1146872 T3 DK1146872 T3 DK 1146872T3 DK 00902628 T DK00902628 T DK 00902628T DK 00902628 T DK00902628 T DK 00902628T DK 1146872 T3 DK1146872 T3 DK 1146872T3
Authority
DK
Denmark
Prior art keywords
angiotensin
treatment
myocardial infarction
receptor antagonists
acute myocardial
Prior art date
Application number
DK00902628T
Other languages
English (en)
Inventor
Jessica M Mann
Pascale Oddou
Eric Michel Neuhart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26153740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1146872(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1146872T3 publication Critical patent/DK1146872T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK00902628T 1999-01-26 2000-01-24 Anvendelse af angiotensin II-receptorantagonister til behandling af akut myokardieinfarkt DK1146872T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99810061 1999-01-26
US46866499A 1999-12-21 1999-12-21

Publications (1)

Publication Number Publication Date
DK1146872T3 true DK1146872T3 (da) 2006-10-16

Family

ID=26153740

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00902628T DK1146872T3 (da) 1999-01-26 2000-01-24 Anvendelse af angiotensin II-receptorantagonister til behandling af akut myokardieinfarkt

Country Status (25)

Country Link
EP (2) EP1146872B1 (da)
JP (1) JP2002535367A (da)
KR (1) KR100674053B1 (da)
CN (1) CN1337879A (da)
AT (1) ATE330599T1 (da)
AU (1) AU766453C (da)
BR (1) BR0007686A (da)
CA (1) CA2360691A1 (da)
CY (1) CY1105257T1 (da)
CZ (1) CZ20012682A3 (da)
DE (1) DE60028928T2 (da)
DK (1) DK1146872T3 (da)
ES (1) ES2265910T3 (da)
HK (1) HK1041808B (da)
HU (1) HUP0105199A3 (da)
ID (1) ID29818A (da)
IL (2) IL144216A0 (da)
NO (1) NO20013459L (da)
NZ (1) NZ513039A (da)
PL (1) PL197161B1 (da)
PT (1) PT1146872E (da)
RU (2) RU2298405C2 (da)
SI (1) SI1146872T1 (da)
SK (1) SK10522001A3 (da)
WO (1) WO2000044378A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200605472T1 (tr) 1998-12-23 2007-02-21 Novartis Ag AT-1 veya AT-2 reseptörlerindeki artışın neden olduğu hastalıkların tedavisi için AT-1 reseptör antagonisti veya AT-2 reseptör modülatörünün kullanımı@
WO2002017913A1 (fr) * 2000-08-30 2002-03-07 Sankyo Company, Limited Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque
US7076287B2 (en) 2000-12-29 2006-07-11 Ge Medical Systems Information Technologies, Inc. System and method for detecting new left bundle branch block for accelerating treatment of acute myocardial infarction
CN1571668A (zh) * 2001-10-18 2005-01-26 诺瓦提斯公司 At1－受体拮抗剂和心血管药物形成的盐
CN1662256A (zh) * 2002-05-17 2005-08-31 诺瓦提斯公司 用于心肌梗死二级预防的血管紧张素Ⅱ受体阻断剂和β－阻断剂的组合
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
SE0302331D0 (sv) * 2003-08-29 2003-08-29 Astrazeneca Ab New use II
WO2005030202A1 (en) * 2003-09-26 2005-04-07 Novartis Ag Use of angiotensin ii receptor antagonists for treating cerebrovascular disorders
WO2005053687A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Combination of organic compounds
WO2009087116A1 (en) * 2008-01-11 2009-07-16 Novartis Ag Use of spp100 for the treatment of acute mi
CN104086623B (zh) * 2014-07-02 2017-05-24 牡丹江友搏药业有限责任公司 一种新的具有降压和细胞保护作用的化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027208D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
EP0577025A3 (de) * 1992-07-01 1998-02-04 Hoechst Aktiengesellschaft Angiotensin-II-Rezeptorantagonisten zur Behandlung und Prophylaxe von koronaren Herzerkrankungen
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
DE4432860A1 (de) * 1994-09-15 1996-03-21 Merck Patent Gmbh Imidazopyridine
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US5795904A (en) * 1996-12-06 1998-08-18 Merck & Co., Inc. Enhanced functional recovery of the heart by losartan treatment after an ischemic attach

Also Published As

Publication number Publication date
IL144216A (en) 2007-07-04
HK1041808B (zh) 2007-01-19
EP1714651A1 (en) 2006-10-25
AU766453C (en) 2004-11-25
DE60028928T2 (de) 2007-01-04
PL197161B1 (pl) 2008-03-31
HUP0105199A2 (hu) 2002-04-29
RU2006135205A (ru) 2008-04-10
DE60028928D1 (de) 2006-08-03
EP1146872A1 (en) 2001-10-24
HK1041808A1 (en) 2002-07-26
NO20013459L (no) 2001-09-05
AU2439700A (en) 2000-08-18
ES2265910T3 (es) 2007-03-01
AU766453B2 (en) 2003-10-16
BR0007686A (pt) 2001-11-06
CA2360691A1 (en) 2000-08-03
IL144216A0 (en) 2002-05-23
CY1105257T1 (el) 2010-03-03
NO20013459D0 (no) 2001-07-12
HUP0105199A3 (en) 2004-11-29
ATE330599T1 (de) 2006-07-15
JP2002535367A (ja) 2002-10-22
CN1337879A (zh) 2002-02-27
EP1146872B1 (en) 2006-06-21
NZ513039A (en) 2003-11-28
RU2345790C2 (ru) 2009-02-10
KR20020002379A (ko) 2002-01-09
CZ20012682A3 (cs) 2001-10-17
ID29818A (id) 2001-10-11
SI1146872T1 (sl) 2006-12-31
KR100674053B1 (ko) 2007-01-25
RU2298405C2 (ru) 2007-05-10
SK10522001A3 (sk) 2001-12-03
PT1146872E (pt) 2006-10-31
WO2000044378A1 (en) 2000-08-03

Similar Documents

Publication Publication Date Title
CY1105257T1 (el) Χρηση των ανταγωνιστων των υποδοχεων της αγγειοτενσινης ii στην θepαπεια του οξεος εμφραγματος του μυοκαρδιου
LV12639B (lv) Bifenilsulfonamidi ka duali angiotenzina un endotelina receptoru antagonisti
ES2091877T3 (es) Uso de antagonistas de la angiotensina ii para la fabricacion de un medicamento para el tratamiento de la hiperuricemia.
AP1718A (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
BR0110079A (pt) Combinação de compostos orgânicos
ATE305781T1 (de) Non-peptidische vasopressin via antagonisten
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
TR200000025T2 (tr) Azetidinilpropilpiperidin türevleri, ara bağlarıyla tacikinin antagonistleri olarak kullanımları.
CY1106365T1 (el) Συνδυασμος ενος αναστολεα pde και ενος ανταγωνιστη υποδοχεων λευκοτριενιου
DK1313485T3 (da) Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
EA200100089A1 (ru) Предотвращение рецидива мигрени
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
TR200101654T2 (tr) Vitronektin resept”r antagonistleri
CY1105321T1 (el) Μη πεπτιδικοι ανταγωνιστες υποδοχεα ccr1 σε συνδυασμο με κυκλοσπορινη α για τη θepαπεια της απορριψης καρδιακου μοσχευματος
CY1105302T1 (el) Μη-πεπτιδιο ανταγωνιστες υποδοχεα ccr1 για την θepαπεια προϊουσης νεφρικης ινωσης
BR0000486A (pt) Antagonistas do neuropeptìdeo y
DE60016769D1 (de) Antagonisten des vitronectin-receptors
WO2000007544A3 (en) Vitronectin receptor antagonists
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
SE0302331D0 (sv) New use II
NO20033634L (no) GLyT-1-inhibitorer
MXPA04001878A (es) Composiciones medicinales que comprenden antagonista del receptor de angiotensina ii.
NO981188D0 (no) 5-HT3-reseptorantagonister for dyskinesi